Discovery of (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4- (2-thienysulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity

Journal of Medicinal Chemistry

Volumn 43, Issue 20, 2000, Pages 3587-3595

  Hunt, J T ^a   Ding, C Z ^a   Batorsky, R ^a   Bednarz, M ^a   Bhide, R ^a   Cho, Y ^a   Chong, S ^a   Chao, S ^a   Gullo Brown, J ^a   Guo, P ^a   Soong Hoon Kim, ^a   Lee, F Y F ^a   Leftheris, K ^a   Miller, A ^a   Mitt, T ^a   Patel, M ^a   Penhallow, B A ^a   Ricca, C ^a   Rose, W C ^a   Schmidt, R ^a   Slusarchyk, W A ^a   Vite, G ^a   Manne, V ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 3 (PHENYLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 DENZODIAZEPINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; COLON TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

3T3 CELLS; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; BIOLOGICAL AVAILABILITY; CELL LINE, TRANSFORMED; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENES, RAS; HUMANS; IMIDAZOLES; MICE; MICE, INBRED BALB C; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034609805     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000248z     Document Type: Article

References (19)

1. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
2. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
3. Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho
4. Inhibitors of protein prenylation 1999
5. Second generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo activity
6. Identification of pharmacokinetically stable 3,10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities
7. Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferase
8. (+)-4-[2-[4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta-[1,2- b]pyridin-11(R)-yl)-1-piperidinyl]-2-oxoethyl]-1-piperidine-carboxamide (Sch-66336): A very potent farnesyl protein transferase inhibitor as a novel antitumor agent
9. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
10. Phase I and pharmcokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
11. Ras farnesylation as a target for novel antitumor agents: Potent and selective farnesyl diphosphate analogue inhibitors of farnesyltransferase
12. Bisubstrate inhibitors of farnesyltransferase: A novel class of specific inhibitors of ras transformed cells
13. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies
14. Potent, non-thiol inhibitors of farnesyltransferase
15. Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase
16. N-arylpiperazinone inhibitors of farnesyltransferase: Discovery and biological activity
17. A generalized wilcoxon test for comparing arbitrarily singly-censored samples